2. Academic Validation
  3. Modified Qianghuo Shengshi Decoction Ameliorates Osteoarthritis via Inhibiting PI3K/Akt Pathway-Related Ferroptosis

Modified Qianghuo Shengshi Decoction Ameliorates Osteoarthritis via Inhibiting PI3K/Akt Pathway-Related Ferroptosis

  • J Cell Mol Med. 2025 Jul;29(13):e70691. doi: 10.1111/jcmm.70691.
Chen Zhuang 1,  Enli Li 2,  Wen-Kai Li 3,  Xiaojuan Geng 4,  Chenxuan Hong 5,  Yu Pan 5 6 7,  Lei Yang 2
Affiliations

Affiliations

  • 1 Alberta Institute, Wenzhou Medical University, Zhejiang, China.
  • 2 Department of Orthopaedics, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China.
  • 3 The First School of Clinical Medicine, Zhejiang Chinese Medical University, Zhejiang, Hangzhou, China.
  • 4 School of Pharmacy, Zhejiang Chinese Medical University, Zhejiang, Hangzhou, China.
  • 5 Quzhou TCM Hospital, Junction of Four Provinces, Affiliated to Zhejiang Chinese Medical University, Zhejiang, China.
  • 6 Quzhou Hospital of Traditional Chinese Medicine, Zhejiang, China.
  • 7 Department of Orthopaedics, The First Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Provincial Hospital of Traditional Chinese Medicine, Zhejiang, Hangzhou, China.
PMID: 40586853 DOI: 10.1111/jcmm.70691
Abstract

Modified Qianghuo Shengshi decoction (MQSD), a TCM formula, is clinically used for osteoarthritis (OA) symptom relief. Its exact molecular actions, however, are not fully understood. This investigation seeks to elucidate the molecular mechanisms by which MQSD impedes OA progression. High performance liquid chromatography (HPLC) was employed to delineate MQSD's chemical profile. The CCK-8 assay determined MQSD's impact on chondrocyte viability in the presence or absence of IL-1β. EDU and Annexin V-FITC assays evaluated chondrocyte proliferation and Apoptosis, respectively. Alcian Blue staining probed extracellular matrix (ECM) secretion by chondrocytes. Network pharmacology was utilised to pinpoint disease targets, while various assays assessed ferroptosis-related chondrocyte phenotypes under Erastin or Ferrostatin-1 treatments. IHC, qRT-PCR and western blot analyses were conducted to ascertain MQSD's cellular effects. Micro-CT and Safranin O Fast Green staining provided insights into knee joint morphology and cartilage integrity. Molecular docking assessed the binding affinity of MQSD's active compounds to PI3K/Akt/GPX4. MQSD promotes chondrocyte proliferation, prevents Apoptosis, and enhances viability. It further modulates the ECM output and the anabolic-to-catabolic ratio within chondrocytes. Through network pharmacology, Ferroptosis linked to the PI3K/Akt pathway is identified as crucial. Pre-application of MQSD elevates the GSH/GSSG ratio and mitochondrial density, while it reduces Fe2+ levels, ROS, and lipid droplet accumulation in chondrocytes. Moreover, MQSD activates GPX4 and inhibits p-AKT levels. Molecular docking studies affirm the strong interaction between MQSD's key ingredients and the PI3K/Akt/GPX4 pathway components. Through modulation of Ferroptosis via the PI3K/Akt pathway, MQSD retards OA progression.

Keywords

PI3K/Akt; TCM; ferroptosis; modified qianghuo shengshi decoction; osteoarthritis.

Figures
Products
Inhibitors & Agonists
Other Products